PriceTargets.com logo

Atea Pharmaceuticals - AVIR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.88
  • Forecasted Upside: 117.72%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$3.16 As of 11/20/2024 01:00 AM ET
▲ +0.02 (0.64%)

This chart shows the closing price for AVIR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Atea Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVIR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVIR

Analyst Price Target is $6.88
▲ +117.72% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Atea Pharmaceuticals in the last 3 months. The average price target is $6.88, with a high forecast of $6.88 and a low forecast of $6.88. The average price target represents a 117.72% upside from the last price of $3.16.

This chart shows the closing price for AVIR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Atea Pharmaceuticals. This rating has held steady since August 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/30/2024William BlairUpgradeStrong-Buy
8/13/2024Morgan StanleyUpgradeUnderweight ➝ Equal Weight$2.00 ➝ $6.88
8/10/2023JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
3/16/2023JPMorgan Chase & Co.Lower TargetNeutral$12.00 ➝ $8.00
1/27/2023Leerink PartnersLower TargetMarket Perform$8.00 ➝ $6.00
1/24/2023Morgan StanleyLower TargetUnderweight$7.00 ➝ $4.00
8/15/2022Morgan StanleyBoost TargetUnderweight$6.00 ➝ $7.00
3/2/2022JPMorgan Chase & Co.Lower TargetNeutral$10.00 ➝ $8.00
3/1/2022Leerink PartnersLower TargetMarket Perform$10.00 ➝ $9.00
2/16/2022Leerink PartnersLower TargetMarket Perform$11.00 ➝ $10.00
1/6/2022Morgan StanleyDowngradeEqual Weight ➝ Underweight$14.00 ➝ $7.00
12/16/2021Leerink PartnersReiterated RatingHold$11.00
11/18/2021Leerink PartnersDowngradeOutperform ➝ Market Perform$11.00
10/20/2021Leerink PartnersLower TargetOutperform$60.00 ➝ $20.00
10/19/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$61.00 ➝ $16.00
10/18/2021JPMorgan Chase & Co.Boost TargetPositive ➝ Overweight$56.00 ➝ $61.00
10/5/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$55.00
9/9/2021Leerink PartnersInitiated CoverageOutperform$60.00
8/18/2021Morgan StanleyBoost TargetOverweight$35.00 ➝ $37.00
6/3/2021Morgan StanleyLower TargetOverweight$82.00 ➝ $35.00
4/6/2021Morgan StanleyBoost TargetOverweight$49.00 ➝ $82.00
1/29/2021JPMorgan Chase & Co.Boost TargetOverweight$45.00 ➝ $66.00
11/24/2020Evercore ISIInitiated CoverageOutperform
11/24/2020Morgan StanleyInitiated CoverageOverweight$49.00
11/24/2020JPMorgan Chase & Co.Initiated CoverageOverweight$45.00
11/24/2020William BlairInitiated CoverageOutperform$60.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 2 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
9/22/2024
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Atea Pharmaceuticals logo
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $3.16
Low: $3.10
High: $3.16

50 Day Range

MA: $3.47
Low: $3.14
High: $4.02

52 Week Range

Now: $3.16
Low: $2.77
High: $4.60

Volume

182,019 shs

Average Volume

296,035 shs

Market Capitalization

$266.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Atea Pharmaceuticals?

The following sell-side analysts have issued research reports on Atea Pharmaceuticals in the last year: Morgan Stanley, and William Blair.
View the latest analyst ratings for AVIR.

What is the current price target for Atea Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Atea Pharmaceuticals in the last year. Their average twelve-month price target is $6.88, suggesting a possible upside of 117.7%. Morgan Stanley has the highest price target set, predicting AVIR will reach $6.88 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $6.88 for Atea Pharmaceuticals in the next year.
View the latest price targets for AVIR.

What is the current consensus analyst rating for Atea Pharmaceuticals?

Atea Pharmaceuticals currently has 1 hold rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AVIR will outperform the market and that investors should add to their positions of Atea Pharmaceuticals.
View the latest ratings for AVIR.

What other companies compete with Atea Pharmaceuticals?

Other companies that are similar to Atea Pharmaceuticals include Inovio Pharmaceuticals, Avadel Pharmaceuticals, Cogent Biosciences, Zymeworks and Bicara Therapeutics. Learn More about companies similar to Atea Pharmaceuticals.

How do I contact Atea Pharmaceuticals' investor relations team?

The company's listed phone number is 857-284-8891 and its investor relations email address is [email protected]. The official website for Atea Pharmaceuticals is www.ateapharma.com. Learn More about contacing Atea Pharmaceuticals investor relations.